Thermo Fisher Scientific Inc. (NYSE:TMO) is Connectus Wealth LLC’s 7th Largest Position

Connectus Wealth LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 179,037 shares of the medical research company’s stock after selling 1,414 shares during the period. Thermo Fisher Scientific accounts for about 1.8% of Connectus Wealth LLC’s investment portfolio, making the stock its 7th biggest holding. Connectus Wealth LLC’s holdings in Thermo Fisher Scientific were worth $95,032,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Ossiam lifted its position in Thermo Fisher Scientific by 5.1% during the 4th quarter. Ossiam now owns 9,217 shares of the medical research company’s stock valued at $4,892,000 after acquiring an additional 447 shares during the period. Personal CFO Solutions LLC raised its holdings in Thermo Fisher Scientific by 2.1% in the fourth quarter. Personal CFO Solutions LLC now owns 2,110 shares of the medical research company’s stock worth $1,120,000 after buying an additional 43 shares during the last quarter. Security National Bank raised its holdings in Thermo Fisher Scientific by 2.7% in the fourth quarter. Security National Bank now owns 9,981 shares of the medical research company’s stock worth $5,298,000 after buying an additional 263 shares during the last quarter. Veritas Investment Partners UK Ltd. raised its holdings in Thermo Fisher Scientific by 37.5% in the fourth quarter. Veritas Investment Partners UK Ltd. now owns 563,192 shares of the medical research company’s stock worth $299,125,000 after buying an additional 153,674 shares during the last quarter. Finally, Waterloo Capital L.P. raised its holdings in Thermo Fisher Scientific by 166.1% in the fourth quarter. Waterloo Capital L.P. now owns 2,350 shares of the medical research company’s stock worth $1,247,000 after buying an additional 1,467 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,000 shares of company stock valued at $18,512,580. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TMO. Citigroup started coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. HSBC lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. The Goldman Sachs Group lifted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $607.94.

Get Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Trading Up 0.2 %

TMO stock traded up $1.25 during mid-day trading on Friday, reaching $581.09. 1,231,957 shares of the stock traded hands, compared to its average volume of 1,173,904. The business has a 50-day moving average price of $575.14 and a two-hundred day moving average price of $555.31. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The stock has a market capitalization of $221.81 billion, a PE ratio of 37.27, a PEG ratio of 2.71 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.